EGS2632

EGS2632 is an orally administered small-molecule drug combination developed by Energesis Pharmaceuticals for the treatment of obesity. It is a proprietary combination of repurposed drugs designed to provide a rapid path to human proof-of-concept and mid-stage clinical development. The candidate is formulated as a once-daily pill and is currently positioned for Phase 2a clinical trials. While the specific molecular targets and the individual components of the combination have not been publicly disclosed, the program represents the company's lead therapeutic effort in addressing weight loss through a small-molecule approach.